PharmAthene, Altimmune deal

PharmAthene and Altimmune will merge into a publicly traded immunotherapeutics company based in Gaithersburg. The newco will retain Altimmune’s name and trade on NYSE MKT under the ticker ALT. Altimmune shareholders will own 58.2% of the combined company. The merger is subject to approval from the shareholders of both companies and is expected to close by the end of 2Q17. ...